Pyrosequencing Assay for BRCA1 Methylation Analysis: Results from a Cross-Validation Study

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epithelial ovarian cancers (EOCs) with BRCA1/BRCA2 mutations respond to PARP inhibitors.
• BRCA1 promoter methylation is a potential biomarker for therapy response, but validation is needed.
• Previous studies show conflicting results due to a lack of validated assays.

Purpose of the Study:

• To validate a pyrosequencing assay for measuring BRCA1 promoter methylation in EOCs.
• To assess the concordance between different pyrosequencing assays for BRCA1 methylation.
• To investigate the clinical relevance of BRCA1 promoter methylation in EOCs.

Main Methods:

• Reciprocal blind investigation of 109 EOCs using two distinct pyrosequencing assays targeting the BRCA1 promoter.
• Comparison of results from the two pyrosequencing assays.
• Analysis of BRCA1 transcript levels in relation to methylation status.

Main Results:

• High concordance was observed between the two pyrosequencing assays for BRCA1 promoter methylation.
• BRCA1 transcript down-regulation was found in EOCs with BRCA1 methylation.
• The pyrosequencing assay is suitable for formalin-fixed, paraffin-embedded tissues.

Conclusions:

• The validated pyrosequencing assay is a reliable method for detecting BRCA1 promoter methylation in EOCs.
• BRCA1 promoter methylation is clinically relevant and linked to reduced BRCA1 transcript levels.
• This assay could be implemented in routine diagnostics to identify EOC patients eligible for PARP inhibitor therapy.